These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 36963353)
1. Multi-model in silico characterization of 3-benzamidobenzoic acid derivatives as partial agonists of Farnesoid X receptor in the management of NAFLD. Mitra S; Halder AK; Ghosh N; Mandal SC; Cordeiro MNDS Comput Biol Med; 2023 May; 157():106789. PubMed ID: 36963353 [TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling, 3D-QSAR and molecular docking studies of benzimidazole derivatives as potential FXR agonists. Sindhu T; Srinivasan P J Recept Signal Transduct Res; 2014 Aug; 34(4):241-53. PubMed ID: 25072161 [TBL] [Abstract][Full Text] [Related]
3. Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease. Qin T; Gao X; Lei L; Feng J; Zhang W; Hu Y; Shen Z; Liu Z; Huan Y; Wu S; Xia J; Zhang L Eur J Med Chem; 2023 Apr; 252():115307. PubMed ID: 37003047 [TBL] [Abstract][Full Text] [Related]
4. Structural Investigation for Optimization of Anthranilic Acid Derivatives as Partial FXR Agonists by in Silico Approaches. Chen M; Yang X; Lai X; Kang J; Gan H; Gao Y Int J Mol Sci; 2016 Apr; 17(4):536. PubMed ID: 27070594 [TBL] [Abstract][Full Text] [Related]
5. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study. Choubey SK; Jeyaraman J J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885 [TBL] [Abstract][Full Text] [Related]
6. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation. Halder AK; Saha A; Saha KD; Jha T J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685 [TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics and 3D-QSAR studies on indazole derivatives as HIF-1α inhibitors. Singh Y; Sanjay KS; Kumar P; Singh S; Thareja S J Biomol Struct Dyn; 2023 May; 41(8):3524-3541. PubMed ID: 35318905 [TBL] [Abstract][Full Text] [Related]
8. On the relationship of anthranilic derivatives structure and the FXR (Farnesoid X receptor) agonist activity. Kronenberger T; Windshügel B; Wrenger C; Honorio KM; Maltarollo VG J Biomol Struct Dyn; 2018 Dec; 36(16):4378-4391. PubMed ID: 29237358 [TBL] [Abstract][Full Text] [Related]
9. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine. Chaudhari HK; Pahelkar A Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898 [TBL] [Abstract][Full Text] [Related]
10. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations. Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912 [TBL] [Abstract][Full Text] [Related]
11. Structural optimization and biological evaluation of 1-adamantylcarbonyl-4-phenylpiperazine derivatives as FXR agonists for NAFLD. Qin T; Gao X; Lei L; Zhang W; Feng J; Wang X; Shen Z; Liu Z; Huan Y; Wu S; Xia J; Zhang L Eur J Med Chem; 2023 Jan; 245(Pt 1):114903. PubMed ID: 36375336 [TBL] [Abstract][Full Text] [Related]
12. Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure-activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism. Gohda K; Iguchi Y; Masuda A; Fujimori K; Yamashita Y; Teno N Bioorg Med Chem Lett; 2021 Jun; 41():128026. PubMed ID: 33839252 [TBL] [Abstract][Full Text] [Related]
13. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors. Tripathy S; Azam MA; Jupudi S; Sahu SK J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860 [TBL] [Abstract][Full Text] [Related]
14. Ghosh A; Panda P; Halder AK; Cordeiro MNDS Front Pharmacol; 2022; 13():1004255. PubMed ID: 36225563 [TBL] [Abstract][Full Text] [Related]
15. A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors. Tripuraneni NS; Azam MA J Biomol Struct Dyn; 2016 Nov; 34(11):2481-92. PubMed ID: 26587754 [TBL] [Abstract][Full Text] [Related]
16. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening. Sindhu T; Srinivasan P Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676 [TBL] [Abstract][Full Text] [Related]
17. Farnesoid X Receptor as a Promising Therapeutic Target for Nonalcoholic Fatty Liver Disease (NAFLD) and the Current Development of Its Agonists. Shen T; Shi A; Wei Y; Luo X; Xi L Discov Med; 2021; 32(167):113-121. PubMed ID: 35220997 [TBL] [Abstract][Full Text] [Related]